

PHARMANUTRA: NEW AREAS OF APPLICATION RECOGNISED FOR SUCROSOMIAL IRON

The technology patented by PharmaNutra Group has collected further testimonies from the scientific community. It has also been confirmed as effective in cases of iron deficiency in chronic inflammatory bowel disease.

December 10th, 2018 - PharmaNutra S.p.A., a leading pharmaceutical company in the iron-based nutritional supplements sector, listed on the AIM Market Italy, reports important new results and applications for Sucrosomial® Technology, the patent that has allowed PharmaNutra Group to gain a leadership position in the production of iron-based nutritional supplements.

The official journal of the Italian Internal Medicine Society, “**Internal and Emergency Medicine Journal**”, has published a study conducted by the group headed by Professor Antonello Pietrangelo, Gastroenterologist and Full Professor of Internal Medicine at Policlinico di Modena Hospital, entitled: [“Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anaemia”](#) .

This is the first full paper on IBD (Inflammatory Bowel Disease) to demonstrate the efficacy and high tolerability of Sucrosomial Iron® for treating iron deficiency, a frequent complication of IBD. The use of Sucrosomial® Iron, supplemented for 12 weeks in a population of 30 subjects with a confirmed diagnosis of Crohn’s disease or ulcerous rectocolitis associated with moderate iron deficiency, significantly improved haemoglobin levels (in 86% of subjects). An improvement was also evident in the progress of the bowel disease during the observation period.

This study thus certifies the value of Sucrosomial® Iron in an area such as sideropenia in the case of IBD, a condition constantly on the rise in recent years: in Italy alone, according to the scientific society IG-IBD (Italian Inflammatory Bowel Disease Group), 200-250 thousand people are estimated to suffer from inflammatory bowel disease.

Germano Tarantino, Scientific Director of PharmaNutra, commented: *“This study confirms and extends the field of application of Sucrosomial® Iron also in subjects with an iron deficit related to inflammatory bowel disease, increasingly frequent these days. It therefore shows that the Sucrosomial® Technology developed and patented by PharmaNutra Group enjoys increasing recognition from the scientific community for its efficacy and excellent tolerability, which makes it very useful in all cases of a lack or reduced nutritional intake of iron”.*

In addition, as regards scientific publications, 2018 has brought a wealth of recognition for PharmaNutra, with a total of 11 publications in indexed international journal, including 9 studies on Sideral iron, 1 study on magnesium (Ultramag®), which demonstrated the efficacy of Sucrosomial® Technology also when applied to magnesium, and 1 publication on Cetilar®, a cetylated fatty acid based cream that aids movement in osteoarthritic joint conditions.

PharmaNutra S.p.A.

Founded and led by General Director Andrea Lacorte and Managing Director Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 79 of them published and with more than 6000 subjects treated with the supplements. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 180 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 70 countries abroad, through 35 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.

Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com
ufficiostampa@sprianocommunication.com